Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®

Trial Profile

Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics
  • Sponsors Bio-Ker
  • Most Recent Events

    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top